For instance, the identification of a BCR–ABL translocation in most Chronic Myeloid Leukemia (CML) patients led to the development of the selective inhibitor Imatinib and improved the 5-year survival to 90% [22,23,24,25]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.